Trichrome staining

Digital Pathology Service Provider, HistoWiz, Expands Laboratory Footprint to Increase Capacity with New Headquarters in Queens

Retrieved on: 
Monday, March 20, 2023

Leading digital histology provider, HistoWiz, Inc. , opens a new 10,197 square foot central laboratory in Queens, New York inside the Alexandria Center for Life Science – Long Island City.

Key Points: 
  • Leading digital histology provider, HistoWiz, Inc. , opens a new 10,197 square foot central laboratory in Queens, New York inside the Alexandria Center for Life Science – Long Island City.
  • The HistoWiz laboratory facility houses the Company’s core histology services group including tissue processing, paraffin embedding, sectioning, and staining (H&E, Trichrome, PAS, etc.)
  • and will allow the Company to expand its capabilities in specialty services including immunofluorescence ( IF ) and in situ hybridization ( ISH ).
  • View the full release here: https://www.businesswire.com/news/home/20230320005063/en/
    HistoWiz's new histology lab in Long Island City will increase capacity and turnaround times for customers in biopharma research.

PharmaNest Presents NASH Digital Pathology and AI Results With a Performance That Compares to Histological Stages and Imaging Methods at the Liver Meeting® | AASLD 2022

Retrieved on: 
Thursday, November 3, 2022

The abstracts highlight the utility and performance of FibroNest, the first multi-vendor quantitative digital Pathology image analysis and translational platform for the assessment of the severity and progression of Fibrosis and disease activity in NASH and Cirrhosis, and other fibrotic conditions.

Key Points: 
  • The abstracts highlight the utility and performance of FibroNest, the first multi-vendor quantitative digital Pathology image analysis and translational platform for the assessment of the severity and progression of Fibrosis and disease activity in NASH and Cirrhosis, and other fibrotic conditions.
  • The first two abstracts are retrospective analysis of liver biopsies from the LiFT Phase 2 trial of LPCN1144 (NCT04134091).
  • The specific details of these abstracts are available on PharmaNest website at fibronest.com/science.
  • As a multi-vendor platform, FibroNest is compatible with all kinds of digital image formats including conventional digital pathology-stained slides (Picro Sirius Red, Trichrome or Antibody stains for fibrosis) acquired by FDA-approved digital pathology scanners and other digital microscopes.

PathAI & Gilead Present Research at ILC' 20 Demonstrating AI Models Accurately and Reproducibly Assess Treatment Response and Disease Progression across Liver Disorders

Retrieved on: 
Friday, August 28, 2020

PathAI machine learning (ML) models were trained to accurately predict histological features of liver disease severity including fibrosis, steatosis, ballooning, and inflammation across 3 liver diseases: NASH, chronic HBV, and PSC.

Key Points: 
  • PathAI machine learning (ML) models were trained to accurately predict histological features of liver disease severity including fibrosis, steatosis, ballooning, and inflammation across 3 liver diseases: NASH, chronic HBV, and PSC.
  • In all cases, models were trained on digitized, whole slide images of hematoxylin and eosin (H&E), trichrome, and/or picrosirius red-stained liver biopsies.
  • "It is exciting to work with long-standing partners, like Gilead, to demonstrate the potential of the PathAI platform, especially for supporting research and development efforts to bring new therapies to patients."
  • Disease progression was associated with higher ML NASH CRN and Ishak fibrosis scores, as well as greater proportionate areas of hepatocellular ballooning and portal inflammation.